PDS Biotechnology (PDSB) will announce quarterly earnings on Wednesday

PDS Biotechnology (PDSB) will announce quarterly earnings on Wednesday


PDS Biotechnology (NASDAQ: PDSB – Get Rating) will release quarterly earnings data ahead of the market opening on Wednesday, May 11. Analysts expect the company to report earnings of ($ 0.23) per share for the quarter. Investors wishing to register for the company’s teleconference can do so using this link.

PDS Biotechnology (NASDAQ: PDSB – Get Rating) last released its earnings results on Thursday, March 31. The company posted ($ 0.22) EPS for the quarter, surpassing analyst consensus estimates of ($ 0.24) by $ 0.02. During the same quarter last year, the company posted ($ 0.16) EPS. On average, analysts expect PDS Biotechnology to post $ -1 EPS for the current fiscal year and $ 0 EPS for the next fiscal year.

PDSB opened at $ 5.67 on Wednesday. The company has a fifty-day moving average price of $ 5.82 and a two-hundred-day moving average price of $ 7.63. PDS Biotechnology has a 52-week low of $ 4.10 and a 52-week high of $ 17.85. The company has a market capitalization of $ 161.31 million, a PE ratio of -8.86 and a beta of 2.33.

Separately, StockNews.com raised PDS Biotechnology stock to a “sell” score in a research note on Saturday, April 9. One analyst rated the stock with a sell rating, one issued a hold rating, and six gave the company a buy rating. According to data from MarketBeat, PDS Biotechnology currently has an average “Buy” rating and a consensus price target of $ 17.43.

Institutional investors have recently increased or decreased their stakes in the business. Geode Capital Management LLC increased its holdings in PDS Biotechnology by 13.0% in Q4. Geode Capital Management LLC now owns 208,117 shares in the company valued at $ 1,685,000 after acquiring an additional 23,873 shares during the period. Morgan Stanley increased its holdings in PDS Biotechnology by 2,254.9% in Q2. Morgan Stanley now owns 65,703 shares of the company valued at $ 825,000 after acquiring an additional 62,913 shares during the period. Millennium Management LLC purchased a new position in PDS Biotechnology in Q4 worth approximately $ 743,000. State Street Corp increased its holdings in PDS Biotechnology by 15.1% in Q4. State Street Corp now owns 72,476 shares of the company worth $ 587,000 after acquiring an additional 9,500 shares during the period. Finally, Marshall Wace LLP increased its holdings in PDS Biotechnology by 18.5% in Q4. Marshall Wace LLP now owns 68,929 shares in the company valued at $ 557,000 after acquiring an additional 10,756 shares during the period. 20.94% of the stock is currently held by hedge funds and other institutional investors.

Information on PDS biotechnology (Get evaluation)

PDS Biotechnology Corporation, a clinical stage biopharmaceutical company, focuses on the development of multifunctional anticancer immunotherapies. Its flagship product is PDS0101 (HPV16), which is in a Phase II clinical trial providing first-line treatment for recurrent / metastatic head and neck cancer, human papillomavirus-associated malignancies, and cervical cancer. .

Featured stories

Earnings History for PDS Biotechnology (NASDAQ: PDSB)



Receive news and assessments for PDS biotechnology every day – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Biotechnology PDS and related companies with MarketBeat.com’s FREE daily newsletter.


PDS Biotechnology (NASDAQ: PDSB – Get Rating) will release earnings data ahead of the market opening on Wednesday, May 11. Analysts expect PDS Biotechnology to post earnings of ($ 0.23) per share for the quarter. People interested in joining the company’s earnings conference call can do so using this link.

PDS Biotechnology (NASDAQ: PDSB – Get Rating) last released its earnings results on Thursday, March 31. The company reported earnings per share ($ 0.22) for the quarter, beating Thomson Reuters’ consensus estimate of ($ 0.24) by $ 0.02. During the same period last year, the company earned ($ 0.16) EPS. On average, analysts expect PDS Biotechnology to post $ -1 EPS for the current fiscal year and $ 0 EPS for the next fiscal year.

Shares of NASDAQ: PDSB opened Wednesday at $ 5.67. The company has a market capitalization of $ 161.31 million, a P / E ratio of -8.86 and a beta of 2.33. The stock’s 50-day moving average is $ 5.82 and its 200-day moving average is $ 7.63. PDS Biotechnology has a 52-week low of $ 4.10 and a 52-week high of $ 17.85.

Separately, StockNews.com raised PDS Biotechnology to a “sale” score in a research report on Saturday, April 9. One analyst rated the stock with a sell rating, one issued a hold rating, and six gave the stock a buy rating. Based on data from MarketBeat.com, the company currently has an average “Buy” rating and an average price target of $ 17.43.

Hedge funds have recently added or reduced their holdings in the stock. Bank of America Corp DE increased its position in PDS Biotechnology by 7,093.1% during the fourth quarter. Bank of America Corp DE now owns 4,172 shares in the company worth $ 34,000 after buying another 4,114 shares in the last quarter. UBS Group AG acquired a new stake in PDS Biotechnology during the third quarter for a value of approximately $ 44,000. Goldman Sachs Group Inc. acquired a new stake in PDS Biotechnology during the third quarter for approximately $ 170,000. DE Shaw & Co. Inc. acquired a new stake in PDS Biotechnology during the fourth quarter valued at approximately $ 240,000. Finally, Dimensional Fund Advisors LP acquired a new stake in PDS Biotechnology during the fourth quarter for approximately $ 282,000. 20.94% of the stock is currently held by institutional investors and hedge funds.

Company profile of PDS Biotecnologie (Get evaluation)

PDS Biotechnology Corporation, a clinical stage biopharmaceutical company, focuses on the development of multifunctional anticancer immunotherapies. Its flagship product is PDS0101 (HPV16), which is in a Phase II clinical trial providing first-line treatment for recurrent / metastatic head and neck cancer, human papillomavirus-associated malignancies, and cervical cancer. .

Featured stories

Earnings History for PDS Biotechnology (NASDAQ: PDSB)



Receive news and assessments for PDS biotechnology every day – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Biotechnology PDS and related companies with MarketBeat.com’s FREE daily newsletter.

.

Leave a Comment

Your email address will not be published.